Results 121 to 130 of about 46,383 (210)

Fisetin as an Antiviral Agent Targeting the RNA-Dependent RNA Polymerase of SARS-CoV-2: Computational Prediction and In Vitro Experimental Validation. [PDF]

Microorganisms
Hernández-Rodríguez X, Lira-Hernández FI, Reyes-Ruíz JM, Osuna-Ramos JF, Farfán-Morales CN, Calderón-Sandate DN, Castañeda-Delgado JE, León-Juárez M, Ángel RMD, Rivas-Santiago B, Noriega S, Cañedo-Figueroa DM, Montaño S, Santos-Mena AO, García-Herrera AC, De Jesús-González LA.   +15 more
europepmc   +1 more source

Persistent Seronegativity and Absence of Intact Proviruses Despite Prolonged Initial Viremia in Early-Treated Perinatal HIV Infection. [PDF]

Open Forum Infect Dis
Charre C, Buseyne F, Mélard A, Gardiennet E, Mariaggi AA, Montange T, Le Chenadec J, Warszawski J, Blanche S, Avettand-Fenoël V, Frange P.   +10 more
europepmc   +1 more source

Phenotypic impacts of treatment-selected mutations in HIV-2 protease on darunavir and lopinavir susceptibility: Evaluating genotypic HIV-2 drug resistance tools. [PDF]

PLOS Glob Public Health
Raugi DN, Nixon RS, Smith RA, Hawes SE, Diallo K, Diallo MB, Faye K, Diaw B, Sy MP, Sall F, Seydi M, Gottlieb GS, University of Washington-Senegal HIV-2 Study Group.   +12 more
europepmc   +1 more source

Advancements in development of novel class of HIV protease inhibitors. [PDF]

Ann Med
Gu WG, Yin GZ, Zhang YP.
europepmc   +1 more source

Pharmacokinetics of lopinavir/ritonavir in second-line treatment of children with HIV in the CHAPAS-4 trial. [PDF]

AIDS
Kamphuis AEM, Kiezebrink T, Waalewijn H, Bamford A, Szubert AJ, Chabala C, Bwakura-Dangarembizi M, Makumbi S, Nangiya J, Mumbiro V, Mulenga V, Musiime V, de Wildt SN, Colbers APH, Gibb DM, Burger DM, CHAPAS-4 trial team.   +16 more
europepmc   +1 more source

Pharmacokinetic Simulation of Optimal Lopinavir and Ritonavir Dose Combination for COVID-19: Boosting Lopinavir With Ritonavir. [PDF]

In Vivo
Nakamaru Y, Sako KI, Ide N, Matsuda Y, Yamashita F, Maeda T.   +5 more
europepmc   +1 more source

Nanoparticles in HIV treatment for improved drug delivery, clinical translation, and future direction. [PDF]

Discov Nano
Terkimbi SD, Dangana RS, Mbina SA, Paul-Chima UO, Aja PM, Mujinya R.   +5 more
europepmc   +1 more source

Cartilage-protective effects of lopinavir/ritonavir: in vitro and in silico exploration of the HIF-1α/SOX9/IL-1β pathway. [PDF]

J Orthop Surg Res
Ozbek H, Yilmaz I, Akyuz A, Pehlivanoglu S, Sirin DY, Albayrak M, Yilmaz OF.   +6 more
europepmc   +1 more source

HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial. [PDF]

J Antimicrob Chemother
Schönenberger CM, Haenggi K, Ringera IK, Luoga E, Bresser M, Mothobi B, Mokhele K, Sando D, Molatelle M, Thahane L, Mnzava D, Ndege R, Hlasoa MM, Kayembe BP, Muhairwe J, Glass TR, Klimkait T, Weisser M, Labhardt ND, Tschumi N, Brown JA.   +20 more
europepmc   +1 more source

AIDS patients suffer higher risk of advanced knee osteoarthritis progression due to lopinavir-induced Zmpste24 inhibition. [PDF]

Bone Res
Kong K, Liu L, Zhang R, Chang Y, Shao Y, Zhao C, Qiao H, Jin M, Chen X, Shi W, Wu X, Fan W, Hu Y, Rong K, Zhang P, Li B, Zhang J, Ma P, Zhang X, Li H, Zhai Z.   +20 more
europepmc   +1 more source